Table 2.
Molecular response (MR) at month 3, 6 and 12 and the time span in months to reach MR3 of the 25%-, 50%-, 75%- and 95%- quantiles (25-Q., 50-Q., 75-Q., 95-Q.) from the moving quantiles analysis for the entire study cohort (all patients) and for the optimal responder group compared to the ELN milestones.
| MR at month 3 | MR at month 6 | MR at month 12 | Time to MR3 [m] | ||
|---|---|---|---|---|---|
| All patients cohort (n = 129 pts) | 25-Q | MR1.6 | MR2.8 | MR3.6 | 8.1 |
| 50-Q | MR1.1 | MR2.2 | MR3.0 | 13.0 | |
| 75-Q | MR0.7 | MR1.5 | MR2.3 | 21.1 | |
| 95-Q | MR0.4 | MR0.8 | MR1.4 | 43.9 | |
| Optimal responder cohort (n = 43 pts) | 25-Q | MR2.3 | MR3.4 | MR4.1 | 6.0 |
| 50-Q | MR1.7 | MR2.9 | MR3.8 | 6.6 | |
| 75-Q | MR1.2 | MR2.5 | MR3.3 | 9.8 | |
| 95-Q | MR0.7 | MR2.2 | MR3.1 | 12.5 | |
| ELN milestones | MR1 | MR2 | MR3 | ||
pts patients, m months.